Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC INDEX(TM) Updated thru DEC 2009
    - OnBioVC 2009 Year-in-Review, now available
    - OnBioVC 1Q10 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • business strategy life science

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Limerick BioPharma (San Francisco, CA) a clinical-stage biopharmaceutical company focused on the modulation of cellular pumps and other transporters, closed a $15M Series C financing. Participants include OVP Venture Partners, ARCH Venture Partners, Sevin Rosen Funds and Altitude Funds.

Intrexon (Blacksburg, VA) a clinical-stage biopharmaceutical company focused on modular inducible cancer immunotherapeutics, closed a $10M Series C bring the total round financing to date of $35M. Participants include New River Management.

Aileron Therapeutics (Cambridge, MA) a pre-clinical large molecule biopharmaceutical company focused on oncology, inflammation and metabolic and infectious diseases, closed a $40M Series D financing. Participants include Excel Medical Ventures, SR One, Lilly Ventures, Roche Venture Fund, Apple Tree Partners and Novartis Venture Funds.

Inimex Pharmaceuticals (Canada) a clinical-stage biopharmaceutical company focused on infectious diseases and inflammatory disorders, closed a $22M Series B financing. Participants include Morningside, Roche Venture Fund, Astellas Venture Management, Advantage Life Science Fund, BC Advantage Funds, BDC Venture Capital, British Columbia Discovery Fund, Canadian Medical Discovery Fund, and Working Opportunity Fund.

XORI (Seattle, WA) a development-stage company focused on a technology for the rapid discovery and development of therapeutic monoclonal antibodies for oncology, immune disorders and infectious disease, closed a $3M Series A financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD, and WRF Capital.
*value was undisclosed

Anaphore (La Jolla, CA) is developing a class of protein therapeutics, Atrimers, to address immune-mediated disease and oncology, closed a $13M Series A bring the total round of financing to $38M. Participants include SR One, Merck Serono Ventures, 5AM Ventures, Apposite Capital and Versant Ventures.

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on therapeutic monoclonal antibodies for inflammatory diseases and immune related disorders, closed a $54.8M series C financing. Participants include BZ Bank Aktiengesellschaft.

NKT Therapeutics (Newton, MA) a pre-clinical stage therapeutic company focused on asthma, closed a $8M Series A financing. Participants include SV Life Sciences and MedImmune Ventures.

« Previous Entries  

to top of page...